Glutamate receptors as a target for Alzheimer's disease--are clinical results supporting the hope?

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of neural transmission. Supplementum

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-7091-6139-5_20PMID 12456065
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300)

  2002cited by this paper
• A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)

  2002cited by this paper
• Dementia severity and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia

  2000cited by this paper
• Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease

  2000cited by this paper
• Frequency and impact of neurologic diseases in the elderly of Europe: A collaborative study of population-based cohorts.

  2000cited by this paper
• Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.

  2000cited by this paper
• Memantine in moderately severe to severe Alzheimer's disease (AD): Results of a placebo-controlled 6-month trial

  2000cited by this paper
• Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine)

  1999cited by this paper
• Challenging the cholinergic hypothesis in Alzheimer disease.

  1999cited by this paper
• Worldwide Prevalence and Incidence of Dementia

  1999cited by this paper
• The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease

  1999cited by this paper
• Severe dementia: a common condition entailing high costs at individual and societal levels

  1999cited by this paper
• Glutamate in CNS disorders as a target for drug development: an update.

  1998cited by this paper
• Glutamate toxicity in chronic neurodegenerative disease.

  1998cited by this paper
• An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease

  1997cited by this paper
• Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.

  1997cited by this paper
• Effects of the Uncompetitive NMDA Receptor Antagonist Memantine on Hippocampal Long‐term Potentiation, Short‐term Exploratory Modulation and Spatial Memory in Awake, Freely Moving Rats

  1996cited by this paper
• Infusion of (+) -MK-801 and memantine -- contrasting effects on radial maze learning in rats with entorhinal cortex lesion.

  1996cited by this paper
• Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms.

  1994cited by this paper
• Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan).

  1993cited by this paper
• Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.

  1992cited by this paper
• Functional Assessment Staging (FAST) in Alzheimer's Disease: Reliability, Validity, and Ordinality

  1992cited by this paper
• Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial.

  1991cited by this paper
• Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?

  1990cited by this paper
• Cost benefits of a medically supervised day treatment program for patients with Alzheimer's disease and other forms of dementia

  1989cited by this paper
• Excitatory amino acids and Alzheimer's disease.

  1989cited by this paper
• A double‐blind, placebo‐controlled trial

  1986cited by this paper
• Pathological verification of ischemic score in differentiation of dementias

  1980cited by this paper

• Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review.

  2022cites this paper
• Assay of Memantine Hydrochloride by UV Spectrophotometer

  2019cites this paper
• Alzheimer’s Disease and Animal Models in Retrospect

  2014cites this paper
• Lipoic Acid, Inflammation and Diseases of the Nervous System 102

  2012cites this paper
• Memantine

  2012cites this paper
• Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors

  2012cites this paper
• Delivery of peptide and protein drugs over the blood-brain barrier.

  2009cites this paper
• Brain Iodine and Other Halogens of Control and Alzheimer’s Diseased Patients: Brain Iodine Deficiency in Alzheimer’s Disease

  2009cites this paper
• Memantine: Reality and Potentiality

  2008cites this paper
• Memantine in the treatment of mild-to-moderate Alzheimer’s disease

  2007cites this paper
• Donepezil‐ or rivastigmine‐induced acetylcholinesterase inactivation is not modulated by neramexane in rat brain

  2007cites this paper
• Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study

  2007cites this paper
• Lipoic acid as a novel treatment for Alzheimer's disease and related dementias.

  2007cites this paper
• Glutamate in the neurobiology and treatment of dementias

  2006cites this paper
• Memantine in the treatment of Alzheimer’s disease

  2006cites this paper
• Coadministration of Memantine with Acetylcholinesterase Inhibitors

  2006cites this paper
• Memantine: Targeting glutamate excitotoxicity in Alzheimer's disease and other dementias

  2005cites this paper
• Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer’s disease

  2005cites this paper
• Dementia and intellectual disability

  2005cites this paper
• Identification of Genes Regulated by Memantine and MK-801 in Adult Rat Brain by cDNA Microarray Analysis

  2004cites this paper
• Memantine: An antiglutamatergic option for dementia

  2004cites this paper
• Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

  2004influential citation
• [Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease].

  2004cites this paper
• Memantine hydrochloride: pharmacological and clinical profile.

  2004cites this paper
• Neuroprotection by fructose-1,6-bisphosphate involves ROS alterations via p38 MAPK/ERK.

  2004cites this paper
• Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil

  2004cites this paper
• Specific Functional Effects of Memantine Treatment in Patients with Moderate to Severe Alzheimer’s Disease

  2004cites this paper
• Mémantine (Ebixa®) : une nouvelle stratégie thérapeutique dans le traitement des formes modérément sévères à sévères de la maladie d’Alzheimer

  2004cites this paper
• Current awareness in geriatric psychiatry. Bibliography.

  2003cites this paper
• Evaluation of memantine for the treatment of Alzheimer’s disease

  2003cites this paper
• Treating the full spectrum of dementia with memantine

  2003cites this paper
• Memantine

  2003cites this paper
• Pharmacologic Management of Agitation in Alzheimer’s Disease

  2003cites this paper